Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Renal Allograft Tolerance Through Mixed Chimerism

Trial Profile

Renal Allograft Tolerance Through Mixed Chimerism

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Mar 2019

At a glance

  • Drugs Rituximab (Primary) ; Siplizumab (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Mar 2019 Planned End Date changed from 1 Oct 2018 to 1 Jun 2019.
    • 12 Dec 2013 Planned end date changed from 1 Aug 2016 to 1 Oct 2018 as reported by ClinicalTrials.gov.
    • 01 Mar 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top